---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087631"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T05:41:43.459488+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fennec Q2 revenue $3.3M (up 98% QoQ); appoints Adrian Haigh as COO

## Summary
- Net product sales of $3.3M for Q2 2023, up 98% from Q1 2023; gross profit $3.2M.
- Net loss of $5.4M ($0.21 diluted EPS) vs $5.1M loss ($0.19) in Q2 2022.
- Cash and equivalents $15.0M; sufficient to fund operations for at least 12 months.
- Adrian Haigh appointed COO, stepping down from board; base salary €400K/yr plus bonus and 200K options.
- Management to present at 2023 Wedbush PacGrow Healthcare Conference on August 8-9.

## SEC filing metadata
- accession: 0001104659-23-087631
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/tm2322902d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087631
- JSON: https://secwatch.observer/filing/0001104659-23-087631.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087631.txt

## Key facts
- Executive change
  Adrian Haigh was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: In the same press release it was announced that Mr. Haigh had accepted the appointment as Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm
- Executive change
  Adrian Haigh departed as Director at FENNEC PHARMACEUTICALS INC..
  - Action: stepped down
  - Role: Director
  source text: Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.